Scholarlink

<p>Bacterial Cellulose (BC) is recognized as a biocompatible and safe polysaccharide that is a promising matrix for drug delivery. To develop a novel dual biopolymer nanocarrier combining bacterial cellulose (BC) and bovine serum albumin nanoparticles (BSANP) are used for sustained delivery of 5-fluorouracil (5-FU) and evaluate its cytotoxicity against HT-29 colorectal cancer cells. 5-FU was encapsulated in BSANP, then loaded onto BC to form 5‑FU.BSANP@BC. The formulation was characterized by FTIR, STA, FESEM, and AFM. Drug release kinetics and mechanisms were studied in physiological conditions, and cytotoxicity was assessed using the MTT assay on HT-29 cells. The 5-FU.BSANP particles exhibited a nearly spherical morphology with an average diameter of 454 ± 177&#xa0;nm, embedded within the BC network, with an average fiber width of 69 ± 13&#xa0;nm. The 5‑FU.BSANP@BC system achieved high drug loading (35.3%) and encapsulation efficiency (65.9%). It exhibited sustained release over 358&#xa0;h with a Fickian diffusion mechanism (Korsmeyer-Peppas model). Compared to 5‑FU@BC, the dual nanocarrier showed significantly higher cytotoxicity against HT-29 cells. Ultimately, the BC/BSANP dual biopolymer platform enables prolonged 5-FU release and enhanced anticancer activity, representing a promising strategy for colorectal cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Dual Biopolymer Nanocarrier (Bacterial Cellulose/Bovine Serum Albumin Nanoparticles) for Sustained 5-Fluorouracil Delivery: Characterization, Sustained Release, and Cytotoxicity in HT-29 Colorectal Cancer Cells

  • 期刊论文

  • 发表日期：

    2026年7月10日

查看全文
  • Malak Nematian,
  • Maryam Saeidifar,
  • Nooshin Salman Tabrizi,
  • Hamidreza Mirzaei

摘要

Bacterial Cellulose (BC) is recognized as a biocompatible and safe polysaccharide that is a promising matrix for drug delivery. To develop a novel dual biopolymer nanocarrier combining bacterial cellulose (BC) and bovine serum albumin nanoparticles (BSANP) are used for sustained delivery of 5-fluorouracil (5-FU) and evaluate its cytotoxicity against HT-29 colorectal cancer cells. 5-FU was encapsulated in BSANP, then loaded onto BC to form 5‑FU.BSANP@BC. The formulation was characterized by FTIR, STA, FESEM, and AFM. Drug release kinetics and mechanisms were studied in physiological conditions, and cytotoxicity was assessed using the MTT assay on HT-29 cells. The 5-FU.BSANP particles exhibited a nearly spherical morphology with an average diameter of 454 ± 177 nm, embedded within the BC network, with an average fiber width of 69 ± 13 nm. The 5‑FU.BSANP@BC system achieved high drug loading (35.3%) and encapsulation efficiency (65.9%). It exhibited sustained release over 358 h with a Fickian diffusion mechanism (Korsmeyer-Peppas model). Compared to 5‑FU@BC, the dual nanocarrier showed significantly higher cytotoxicity against HT-29 cells. Ultimately, the BC/BSANP dual biopolymer platform enables prolonged 5-FU release and enhanced anticancer activity, representing a promising strategy for colorectal cancer therapy.